Pyridinyl 4-(2-oxoalkylimidazolidin-1-yl)benzenesulfonates and their hydrochloride salts as novel water soluble antimitotic prodrugs bioactivated by cytochrome P450 1A1 in breast cancer cells-Reference-Cited by-同舟云学术

Pyridinyl 4-(2-oxoalkylimidazolidin-1-yl)benzenesulfonates and their hydrochloride salts as novel water soluble antimitotic prodrugs bioactivated by cytochrome P450 1A1 in breast cancer cells

Published:2024 Issue: Volume: Page:
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Ouellette Vincent¹²^ORCID,Bouzriba Chahrazed¹²^ORCID,Chavez Alvarez Atziri Corin¹²³^ORCID,Bruxelles Quentin¹²,Hamel-Côté Geneviève¹,Fortin Sébastien¹²^ORCID

Affiliation:

1. Hôpital Saint-François d'Assise, Centre de recherche du CHU de Québec – Université Laval, Axe Oncologie, 10 Rue de l'Espinay, Québec, QC, G1L 3L5, Canada

2. Faculté de pharmacie, Université Laval, Québec, QC, G1V 0A6, Canada

3. Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, 2725 Ch Ste-Foy, Québec, QC, G1V 4G5, Canada

Abstract

New water soluble antimitotic CYP1A1-activated prodrugs named PYRAIB-SOs and their hydrochlorides targeting breast cancers.

Funder

Natural Sciences and Engineering Research Council of Canada

Canada Foundation for Innovation

Fonds de Recherche du Québec - Santé

Réseau Québécois de Recherche sur les Médicaments

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D4MD00476K

Reference60 articles.

1. World Health Organization, Globocan, Cancer today - IARC, https://gco.iarc.who.int/en , (accessed 25 January, 2024)

2. American Cancer Society, Survival rates for breast cancer, https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html , (accessed 25 January, 2024)

Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

4. Recent advances in radiotherapy of breast cancer

5. Adjuvant and neoadjuvant therapy for breast cancer